There are 3397 resources available
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04